Feature | August 30, 2012

Peripheral Vascular Procedures Moving Increasingly to Outpatient Setting

Millennium Research Group’s new physician forum report provides details of physician attitudes and choices

August 30, 2012 — According to Millennium Research Group (MRG), an authority on the medical technology market, as significant numbers of peripheral vascular and vascular access procedures move out of the hospital setting and into a variety of outpatient facilities, manufacturers of peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters will face new and complex challenges in marketing their products.

Physician preference is the main driving force in moving procedures into these facilities. Aside from the increased flexibility in scheduling procedures, physicians are particularly interested in the favorable reimbursement they receive for these procedures. Specialized vascular access centers have sprung up in the past five to 10 years, but many of these procedures are also performed in physician offices and in existing dialysis centers. The range of facility types is wide, making it difficult for manufacturers to target them effectively.

Physicians who run their own centers tend to have limited brand loyalty, but do keep a sharp eye on the bottom line, creating incentives for manufacturers to offer attractive pricing. If manufacturers are to succeed in appealing to this market, they need a deeper understanding of how these physicians acquire information and make purchasing decisions.

These results come from a new MRG report, Outpatient Vascular Treatment Centers Study, part of its Physician Forum series. Physician Forum reports are produced in response to specific market events and trends that are expected to have significant effects on the utilization and sales of medical devices. This report was published in June 2012.

The results are based on surveys that were conducted from March to May 2012 and included 90 respondents in vascular access centers, office-based practices and dialysis centers who have performed a significant number of interventional procedures. Survey respondents were interventional cardiologists, interventional nephrologists, interventional radiologists, nephrologists and vascular surgeons in the United States.

“There is a lot of variation between which procedures different centers and practices will be focusing on in the near future,” said MRG Manager Stephanie LaBelle. “Some are looking to increase their volume of lucrative vein treatments such as varicose vein ablation and sclerotherapy, while others will be specializing in peripheral artery disease, and expanding their atherectomy procedure volumes. Manufacturers need to make sure they have the most updated information on this rapidly changing market.”

Millennium Research Group’s Outpatient Vascular Treatment Centers Study report provides information about physician attitudes and purchase decision criteria for peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloons, atherectomy devices, thrombectomy devices and dialysis catheters used in vascular access centers, office-based practices and dialysis centers.

For more information: www.MRG.net

Related Content

Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

News | Stents Peripheral| September 28, 2015
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Overlay Init